Abstract:Abstract: Chimeric antigen receptor T-cells, known as CAR-T cells, represent a promising breakthrough in the realm of adoptive cell therapy. These T-cells are genetically engineered to carry chimeric antigen receptors that specifically target tumors. They have achieved notable success in the treatment of blood-related cancers, breathing new life into this field of medical research. However, numerous obstacles limit chimeric antigen receptors T-cell therapy's efficacy, such as it cannot survive in the body long. It is prone to fatigue and exhaustion, leading to difficult tumor elimination and repeated recurrence, affecting solid tumors and hematological malignancies. The challenges posed by solid tumors, especially in the context of the complex solid-tumor microenvironment, require specific strategies. This review outlines recent advancements in improving chimeric antigen receptors T-cell therapy by focusing on the chimeric antigen receptors protein, modifying T-cells, and optimizing the interaction between T-cells and other components within the tumor microenvironment. This article aims to provide an extensive summary of the latest discoveries regarding CAR-T cell therapy, encompassing its application across various types of human cancers. Moreover, it will delve into the obstacles that have emerged in recent times, offering insights into the challenges faced by this innovative approach. Finally, it highlights novel therapeutic options in treating hematological and solid malignancies with chimeric antigen receptors T-cell therapies.

Current Status and Problems of Chimeric Antigen Receptor T Cell Immunotherapy in Treatment of Hematological Malignancies

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Current progress in CAR-T cell therapy for tumor treatment

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

Current state of CAR-T therapy for T-cell malignancies

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

CAR-T Cell Therapy: Where Are We Now, and Where Are We Heading?

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies